|Number of samples:||13|
|Release date:||Jan 5 2016|
|Last update date:||Oct 18 2018|
|Diseases:||Leukemia, Lymphoid, Multiple Myeloma|
|Dataset link||Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma (ChIP-Seq)|
A total of 13 ChIP-seq samples were sequenced. Samples were treated with control (DMSO) or test compound (2.5 uM SGC-CBP30 or 0.25uM CPI267203) for 6 hours. Signal from input samples was included to subtract background signal from each ChIP-seq sample. Antibodies used were against p300, H3K18ac, H3K27ac, or BRD4.
Barbara M Bryant